ArticleHematological oncology2025
Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy.
Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R-chemo or R2. With data of sequential PET/CT at the baseline, interim, and end-of-induction, treatment responses and survival outcomes were analyzed using Deauville scores at the interim and end-of-induction. Additionally, correlations between interim Deauville scores and baseline PET/CT parameters were explored. Conclusively, we revealed that Deauville 1-3 at the interim and end-of-induction showed lower disease progression within 24 months (POD24) and superior progression-free survival (PFS) in R-chemo and R2 cohorts. Also, patients with interim Deauville 1-3 exhibited reduced POD24 and favorable PFS as compared to those with interim Deauville 4-5/end-of-induction Deauville 1-3. Furthermore, total lesion glycolysis of baseline PET-CT surpassed standardized uptake value and total metabolic tumor volume in predicting interim Deauville 1-3, with different optimal cutoffs of 2600 and 600 mL in the R-chemo and R2 cohort. These findings underscored the potential of PET-CT-adapted strategies to achieve durable remission in FL undergoing rituximab-based immunochemotherapy or immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.